These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35741624)

  • 21. Altered gut microbiota in patients with idiopathic Parkinson's disease: an age-sex matched case-control study.
    Babacan Yildiz G; Kayacan ZC; Karacan I; Sumbul B; Elibol B; Gelisin O; Akgul O
    Acta Neurol Belg; 2023 Jun; 123(3):999-1009. PubMed ID: 36719617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression.
    Aho VTE; Pereira PAB; Voutilainen S; Paulin L; Pekkonen E; Auvinen P; Scheperjans F
    EBioMedicine; 2019 Jun; 44():691-707. PubMed ID: 31221587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease.
    Ren T; Gao Y; Qiu Y; Jiang S; Zhang Q; Zhang J; Wang L; Zhang Y; Wang L; Nie K
    Front Neurol; 2020; 11():137. PubMed ID: 32161568
    [No Abstract]   [Full Text] [Related]  

  • 24. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 25. Alterations of gut microbiota and metabolome with Parkinson's disease.
    Yan Z; Yang F; Cao J; Ding W; Yan S; Shi W; Wen S; Yao L
    Microb Pathog; 2021 Nov; 160():105187. PubMed ID: 34530073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
    Martínez-Martín P; Rodríguez-Blázquez C; Forjaz MJ; Alvarez-Sánchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martínez-Castrillo JC; Mendoza-Rodríguez A; Moore HP; Rodríguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    Eur J Neurol; 2014 Mar; 21(3):519-24. PubMed ID: 24447695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral, Nasal, and Gut Microbiota in Parkinson's Disease.
    Li Z; Lu G; Luo E; Wu B; Li Z; Guo J; Xia Z; Zheng C; Su Q; Zeng Y; Chan WY; Su X; Qiu X; Zheng X; Cai Q; Xu Y; Chen Y; Fan Y; Chen W; Yu Z; Chen X; Zheng C; Wang M; Poon WS; Luo X
    Neuroscience; 2022 Jan; 480():65-78. PubMed ID: 34695538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
    Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
    Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal Monitoring of Parkinson's Disease in Different Ethnic Cohorts: The DodoNA and LONG-PD Study.
    Markopoulou K; Aasly J; Chung SJ; Dardiotis E; Wirdefeldt K; Premkumar AP; Schoneburg B; Kartha N; Wilk G; Wei J; Simon KC; Tideman S; Epshteyn A; Hadsell B; Garduno L; Pham A; Frigerio R; Maraganore D
    Front Neurol; 2020; 11():548. PubMed ID: 32733352
    [No Abstract]   [Full Text] [Related]  

  • 33. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.
    Barichella M; Severgnini M; Cilia R; Cassani E; Bolliri C; Caronni S; Ferri V; Cancello R; Ceccarani C; Faierman S; Pinelli G; De Bellis G; Zecca L; Cereda E; Consolandi C; Pezzoli G
    Mov Disord; 2019 Mar; 34(3):396-405. PubMed ID: 30576008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease.
    Cova I; Di Battista ME; Vanacore N; Papi CP; Alampi G; Rubino A; Valente M; Meco G; Contri P; Di Pucchio A; Lacorte E; Priori A; Mariani C; Pomati S
    Parkinsonism Relat Disord; 2017 Jan; 34():38-42. PubMed ID: 28029554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease.
    Sun BH; Wang T; Li NY; Wu Q; Qiao J
    World J Gastrointest Pharmacol Ther; 2021 Jan; 12(1):21-31. PubMed ID: 33564494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of unilateral subthalamic deep brain stimulation in highly asymmetrical Parkinson's disease: 7-year follow-up.
    Ehm G; Kim HJ; Kim JY; Lee JY; Kim HJ; Yun JY; Kim YE; Yang HJ; Lim YH; Jeon B; Paek SH
    J Neurosurg; 2019 Nov; 131(5):1508-1513. PubMed ID: 30497175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease.
    Cirstea MS; Yu AC; Golz E; Sundvick K; Kliger D; Radisavljevic N; Foulger LH; Mackenzie M; Huan T; Finlay BB; Appel-Cresswell S
    Mov Disord; 2020 Jul; 35(7):1208-1217. PubMed ID: 32357258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder.
    Nishiwaki H; Hamaguchi T; Ito M; Ishida T; Maeda T; Kashihara K; Tsuboi Y; Ueyama J; Shimamura T; Mori H; Kurokawa K; Katsuno M; Hirayama M; Ohno K
    mSystems; 2020 Dec; 5(6):. PubMed ID: 33293403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.